Status:
RECRUITING
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
University of Massachusetts, Boston
Conditions:
Breast Cancer
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal...
Detailed Description
This is a randomized control trial of Black and Hispanic patients who have been newly diagnosed with breast, colorectal, or prostate cancer and are being prescribed chemotherapy to determine the effec...
Eligibility Criteria
Inclusion
- Over 18 years old; children under the age of 18 will be excluded due to rarity of disease
- Newly diagnosed with stage I-III breast, colorectal or prostate cancer
- Self-identify as Hispanic or Black
- Are within 4 weeks of initiating chemotherapy
- Overweight or obese (BMI \>25kg/m2 or body fat percent \>30)
- Physician's clearance to participate in moderate-vigorous intensity exercise
- Speak English or Spanish
- Engaging in less than 90 minutes of moderate-or-vigorous physical activity per week
- Willing to travel to Dana-Farber Cancer Institute for necessary data collection
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Pre-existing musculoskeletal or cardiorespiratory conditions
- Patients should not have any uncontrolled illness including ongoing or active infection, uncontrolled diabetes, hypertension, or thyroid disease
- Patients with other active malignancies
- Patients with metastatic disease
- Participate in more than 90 minutes of structured exercise/week
- Unable to travel to Dana-Farber Cancer Institute for necessary data collection
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Key Trial Info
Start Date :
October 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT05327452
Start Date
October 31 2022
End Date
May 31 2026
Last Update
September 23 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215